September 18, 2014 11:33 AM ET

Pharmaceuticals

Company Overview of Arisaph Pharmaceuticals, Inc.

Company Overview

Arisaph Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing therapies for cancer, cardiovascular disease, and diabetes. Its products include dipeptidylpeptidase IV inhibitors, stable GLP-1 agonists, HDL modulators and plaque reducers, and tumor activated pro-soft drugs. Arisaph Pharmaceuticals, Inc. was formerly known as Triad Pharmaceuticals, Inc. and changed its name to Arisaph Pharmaceuticals, Inc. in November 2005. The company was incorporated in 1999 and is based in Boston, Massachusetts.

100 High Street

Suite 1202

Boston, MA 02110

United States

Founded in 1999

Phone:

617-986-4500

Fax:

617-986-4501

Key Executives for Arisaph Pharmaceuticals, Inc.

Co-Founder
Age: 49
Co-Founder and Director
Age: 85
Chief Business Officer and Vice President of Finance
Senior Vice President of Drug Development
Compensation as of Fiscal Year 2014.

Arisaph Pharmaceuticals, Inc. Key Developments

Arisaph Pharmaceuticals, Inc. Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 02:55 PM

Arisaph Pharmaceuticals, Inc. Presents at 2013 Therapeutic Area Partnerships Conference, Nov-19-2013 02:55 PM. Venue: One Avenue De Lafayette, Boston, MA 02111, United States.

Arisaph Pharmaceuticals Reports Positive Results from Two Safety Clinical Trials for its Niacin Analog (ARI-3037MO)

Arisaph Pharmaceuticals, Inc. announced during an oral presentation at the American Heart Association (AHA) meeting in Los Angeles, CA that its niacin analog, ARI-3037MO, was extremely well tolerated in a single-ascending dose (SAD) and a multiple-ascending dose (MAD) trial in healthy male and female volunteers. The results showed that ARI-3037MO did not provoke flushing or any other adverse skin changes, nor did it cause increases in liver enzymes or blood glucose at doses up to 6 grams per day. In both clinical trials, ARI-3037MO also demonstrated encouraging lipid effects. Based on these promising results, ARI-3037MO potentially represents a transformational, new niacin-like option for treatment of patients with dyslipidemia, especially in the setting of metabolic syndrome, a disorder that afflicts as many as 70 million Americans. In two placebo controlled, safety and pharmacokinetic trials (SAD and MAD), 58 healthy male and female volunteers were given either single escalating doses of ARI-3037MO (up to 6 grams per day) or repeat escalating doses of ARI-3037MO (up to 3.5 grams per day) for 14 days. In both trials, ARI-3037MO was given once daily without a titration scheme. The results showed that ARI-3037MO was extremely well tolerated with no treatment-related adverse events. Specifically, treatment with ARI-3037MO did not show any evidence of flushing or adverse skin changes, such as itching or rash, using a validated visual-analog scale. Additionally, no deleterious changes in liver enzymes or blood glucose were observed with ARI-3037MO, even when given at high doses in a repeat-dose setting. The pharmacokinetics of ARI-3037MO revealed that the drug was well absorbed orally and showed good dose proportionality. In both clinical trials, ARI-3037MO produced encouraging lipid signals. For example, a single dose of 6 grams of ARI-3037MO produced a 15% increase in HDL and attenuated the postprandial increase in serum triglycerides (TGs). In the MAD trial, the 2g and 3.5g doses of ARI-3037MO decreased LDL-cholesterol (LDL-C) from baseline and improved post-prandial triglycerides by more than 30% compared with placebo. Such lipid trends are encouraging considering that the trials were short-duration, safety and pharmacokinetic studies in healthy volunteers and would not be expected to show pharmacodynamic effects.

Similar Private Companies By Industry

Company Name Region
Selexys Pharmaceuticals Corporation United States
GenePharm, Inc. United States
Bilcare Inc. United States
Ceva Holdings Inc. United States
Galera Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
October 17, 2013
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Arisaph Pharmaceuticals, Inc., please visit www.arisaph.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.